Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 10237–10238.

https://doi.org/10.1182/blood-2022-166555

Published: 2022

Journal Articles

CD123 and CD33 Co-Targeting By Balanced Signaling on CAR-CIK Cells Reduces Potential Off-Target Toxicity While Preserving the Anti-Leukemic Activity of Acute Myeloid Leukemia

Vincenzo Maria Perriello, Maria Caterina Rotiroti, Ilaria Pisani, Gaia Alberti, Giulia Pianigiani, Roberta Rossi, Valerio Ciaurro, Marta Serafini, Maria Paola Martelli, Brunangelo Falini, Andrea Biondi, Sarah Tettamanti

Blood (2021) 138 (Supplement 1): 1699.

https://doi.org/10.1182/blood-2021-150487

Published: 2021

Journal Articles

CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

Blood (2020) 136 (Supplement 1): 53–54.

https://doi.org/10.1182/blood-2020-139605

Published: 2020

Journal Articles

Preclinical Assessment of Non-Virally Engineered CD33.CAR Cytokine-Induced Killer (CIK) Cells in Chemoresistant AML Patient-Derived Xenografts

Maria Caterina Rotiroti, PhD, Chiara Buracchi, PhD, Silvia Arcangeli, PhD, Chiara F Magnani, PhD, Claudia Cappuzzello, PhD, Zsuzsanna Izsvak, PhD, Stefania Galimberti, PhD, Maria Grazia Valsecchi, PhD, Giuseppe Dastoli, MD, Marta Serafini, PhD, Ettore Biagi, MD, Andrea Biondi, MD, Sarah Tettamanti, PhD

Blood (2019) 134 (Supplement_1): 2665.

https://doi.org/10.1182/blood-2019-130399

Published: 2019

Journal Articles

Specific Targeting of Acute Myeloid Leukemia By the Use of Non-Virally Engineered CIK (Cytokine-Induced Killer) Cells Expressing the Anti-CD33 Chimeric Antigen Receptor (CAR)

Maria Caterina Rotiroti, MSc, Silvia Arcangeli, PhD, Chiara Buracchi, PhD, Chiara Francesca Magnani, PhD, Claudia Cappuzzello, PhD, Ettore Biagi, MD, Sarah Tettamanti, PhD, Andrea Biondi, MD

Blood (2018) 132 (Supplement 1): 2201.

https://doi.org/10.1182/blood-2018-99-114572

Published: 2018

Journal Articles

Balance of Anti-CD123 Chimeric Antigen Receptor (CAR) Binding Affinity and Density for the Treatment of Acute Myeloid Leukemia

Silvia Arcangeli, PhD, Marco Bardelli, PhD, Maria Caterina Rotiroti, Luca Simonelli, PhD, Chiara F. Magnani, PhD, Luca Varani, PhD, Andrea Biondi, MD, Ettore Biagi, MD, Sarah Tettamanti, PhD

Blood (2016) 128 (22): 2163.

https://doi.org/10.1182/blood.V128.22.2163.2163

Published: 2016

Journal Articles

Unraveling the Efficacy and Safety Profiles of Anti-CD123 Chimeric Antigen Receptors (CARs) in a Model of Acute Myeloid Leukemia Immunotherapy By Investigating CAR Binding Affinity and Density Variables

Silvia Arcangeli, Marco Bardelli, Sarah Tettamanti, Maria Caterina Rotiroti, Luca Simonelli, Chiara F Magnani, Luca Varani, Andrea Biondi, Prof, MD, Ettore Biagi, MD

Blood (2015) 126 (23): 1359.

https://doi.org/10.1182/blood.V126.23.1359.1359

Published: 2015

NARROW

Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia

CD123 and CD33 Co-Targeting By Balanced Signaling on CAR-CIK Cells Reduces Potential Off-Target Toxicity While Preserving the Anti-Leukemic Activity of Acute Myeloid Leukemia

CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

Preclinical Assessment of Non-Virally Engineered CD33.CAR Cytokine-Induced Killer (CIK) Cells in Chemoresistant AML Patient-Derived Xenografts

Specific Targeting of Acute Myeloid Leukemia By the Use of Non-Virally Engineered CIK (Cytokine-Induced Killer) Cells Expressing the Anti-CD33 Chimeric Antigen Receptor (CAR)

Balance of Anti-CD123 Chimeric Antigen Receptor (CAR) Binding Affinity and Density for the Treatment of Acute Myeloid Leukemia

Unraveling the Efficacy and Safety Profiles of Anti-CD123 Chimeric Antigen Receptors (CARs) in a Model of Acute Myeloid Leukemia Immunotherapy By Investigating CAR Binding Affinity and Density Variables

Email alerts

ASH Publications

American Society of Hematology

Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia

CD123 and CD33 Co-Targeting By Balanced Signaling on CAR-CIK Cells Reduces Potential Off-Target Toxicity While Preserving the Anti-Leukemic Activity of Acute Myeloid Leukemia

CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

Preclinical Assessment of Non-Virally Engineered CD33.CAR Cytokine-Induced Killer (CIK) Cells in Chemoresistant AML Patient-Derived Xenografts

Specific Targeting of Acute Myeloid Leukemia By the Use of Non-Virally Engineered CIK (Cytokine-Induced Killer) Cells Expressing the Anti-CD33 Chimeric Antigen Receptor (CAR)

Balance of Anti-CD123 Chimeric Antigen Receptor (CAR) Binding Affinity and Density for the Treatment of Acute Myeloid Leukemia

Unraveling the Efficacy and Safety Profiles of Anti-CD123 Chimeric Antigen Receptors (CARs) in a Model of Acute Myeloid Leukemia Immunotherapy By Investigating CAR Binding Affinity and Density Variables

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only